In an animal model of multiple sclerosis, early preventive treatment with the integrated stress response modulator Sephin1 protected visual pathway structure and function during acute inflammatory demyelination. Multiple sclerosis produces extensive inflammatory demyelination, axonal injury, and synaptic pathology that culminate in progressive neurodegeneration across the central nervous system. While Sephin1 has previously been shown to decrease clinical severity and safeguard spinal cord myelin, oligodendrocytes, and axons in experimental autoimmune encephalomyelitis, standard disease scoring primarily reflects motor disability. Consequently, researchers evaluated whether Sephin1 preserves function and architecture within a defined, functionally accessible central nervous system circuit by examining the murine visual pathway.
To investigate circuit-specific therapeutic outcomes, investigators induced experimental autoimmune encephalomyelitis in C57BL/6J mice via immunization with myelin oligodendrocyte glycoprotein peptide 35–55. The experimental design evaluated distinct administration schedules: prophylactic delivery began seven days after induction and continued through peak disease, whereas therapeutic delivery was initiated at the onset of clinical symptoms and continued either through chronic disease or for an isolated seven-day duration. Functional integrity was assessed using recordings of the optomotor response to determine visual acuity, pattern-stimulated visual evoked potentials to capture cortical responses, and pattern electroretinography to evaluate retinal activity. Circuit pathology was evaluated across the retina, optic nerve, and lateral geniculate nucleus through immunohistochemistry alongside RNA in situ hybridization.
Prophylactic administration of Sephin1 successfully reduced overall clinical severity and maintained visual acuity at peak disease. Functional electrophysiological assessments revealed that prophylactic Sephin1 preserved pattern-stimulated visual evoked potential N1 amplitudes, demonstrating maintenance of visually evoked cortical response magnitudes during acute inflammation. In contrast, pattern-stimulated visual evoked potential latency, pattern electroretinography responses, and total retinal ganglion cell counts were not significantly altered at this peak disease stage, indicating that cortical response preservation occurred prior to measurable gross retinal loss.
Histological analyses demonstrated that prophylactic Sephin1 treatment directly preserved optic nerve myelin, oligodendrocytes, and axonal structures. Downstream within the lateral geniculate nucleus, treatment protected retinogeniculate axons and maintained retinal ganglion cell presynaptic terminals. Interestingly, these protective structural and functional outcomes occurred without any detectable reduction in optic nerve CD45-positive immune cell accumulation, CD3-positive T-cell infiltration, reactive astrogliosis, or inflammatory microglial responses, showing that neuroprotection occurred independently of broad immune suppression in the optic nerve tissue.
Molecular evaluations of optic nerve tissue revealed that Sephin1 treatment enhanced key downstream indicators of the integrated stress response pathway. Sephin1-treated nerves exhibited increased phosphorylation of eukaryotic translation initiation factor 2 alpha, which represents the core initiating event of the integrated stress response. In parallel, treated tissues displayed elevated transcript levels of the integrated stress response target gene Ddit3, accompanied by an increased presence of cleaved caspase-3-positive cells relative to complete Freund’s adjuvant controls.
Despite the structural and functional protections observed when treatment spanned the prophylactic-to-peak phase, initiating Sephin1 at clinical symptom onset failed to confer lasting protection. Neither continuous onset-initiated administration through chronic disease nor a short seven-day course preserved visual acuity in chronic stages. Furthermore, continuous therapeutic treatment from onset did not maintain chronic retinal ganglion cell populations, indicating that enhancing the integrated stress response as a standalone therapy possesses a constrained therapeutic window in experimental visual pathway injury.
Subject of Research: Visual circuit protection and myelin preservation by Sephin1 in experimental autoimmune encephalomyelitis
Article Title: Sephin1 protects visual circuit function and structural integrity through myelin preservation during experimental autoimmune encephalomyelitis
Article References: Mey, G. M., Classe, M. J., Staples, J. N., Chen, Y., & Werneburg, S. (2026). Sephin1 protects visual circuit function and structural integrity through myelin preservation during experimental autoimmune encephalomyelitis. Acta Neuropathologica Communications. https://doi.org/10.1186/s40478-026-02488-4
Image Credits: AI Generated
DOI: 10.1186/s40478-026-02488-4
Keywords: multiple sclerosis, experimental autoimmune encephalomyelitis, Sephin1, integrated stress response, visual pathway, optomotor response, visual evoked potentials, pattern electroretinography, retinal ganglion cells, optic nerve, lateral geniculate nucleus, myelin preservation, oligodendrocytes, axonal protection, neurodegeneration, demyelination, eIF2alpha phosphorylation, Ddit3
News Source: Ophelia Keating. (November 20, 2026). Prophylactic Sephin1 Preserves Mouse Visual Circuit Structure and Function in Autoimmune Encephalomyelitis. Scienmag.



